The technology is a new method for: (1) detecting and measuring active and clinically-relevant migration of CTL towards tumor cells; (2) characterization of migrating CTL phenotype and function; (3) In vitro identification of chemokines and cytokines that affect active migration of CTL towards cancer cells; and (4) cloning of relevant tumor antigens that are recognized by migrating CTL. This technology may be useful for the development of systems or kits to measure responses of CTL to various stimuli such as tumor antigens and cytokines.

U.S. Patent No. 7,544,465.

This technology is available for exclusive or non-exclusive license.

Zhang T, Somasundaram R, Berking C, Caputo L, Van Belle P, Elder D, Czerniecki B, Hotz S, Schuchter L, Spitz FR, Berencsi K, Rani P, Marincola F, Qiu R, Herlyn D. (2006) “Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells.” Cancer Biol Ther. 5(10):1304-1312.

Berencsi K, Meropol NJ, Hoffman JP, Sigurdson E, Giles L, Rani P, Somasundaram R, Zhang T, Kalabis J, Caputo L, Furth E, Swoboda R, Marincola F, Herlyn D. (2007) “Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture.” Cancer Immunol Immunother. 56(3):359-370.

Zhang T, Somasundaram R, Berencsi K, Caputo L, Gimotty P, Rani P, Guerry D, Swoboda R, Herlyn D.  (2006) “Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4.” Eur J Immunol. 36(2):457-467.

Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D. (2005) “CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture.” J Immunol. 174(9):5856-5863.